165 related articles for article (PubMed ID: 25469883)
1. Morphologic and molecular backgrounds for personalized management of genito-urinary cancers: an overview.
Montironi R; Santoni M; Lopez-Beltran A; Cheng L; Moch H; Scarpelli M
Curr Drug Targets; 2015; 16(2):96-102. PubMed ID: 25469883
[TBL] [Abstract][Full Text] [Related]
2. Genitourinary cancers: molecular determinants for personalized therapies.
Mazzucchelli R; Gasparrini S; Galosi AB; Massari F; Raspollini MR; Scarpelli M; Lopez-Beltran A; Cheng L; Montironi R
Urologia; 2016 Sep; 83(3):107-109. PubMed ID: 27338983
[TBL] [Abstract][Full Text] [Related]
3. Present and future of personalized medicine in adult genitourinary tumors.
Ciccarese C; Santoni M; Massari F; Cheng L; Lopez-Beltran A; Scarpelli M; Conti A; Tortora G; Cascinu S; Montironi R
Future Oncol; 2015; 11(9):1381-8. PubMed ID: 25952784
[TBL] [Abstract][Full Text] [Related]
4. Morphological and molecular backgrounds for personalized therapies in genitourinary cancers.
Montironi R; Scarpelli M; Santoni M; Lopez-Beltran A; Cheng L
Curr Drug Targets; 2015; 16(2):94-5. PubMed ID: 25668146
[No Abstract] [Full Text] [Related]
5. Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy.
Cimadamore A; Scarpelli M; Santoni M; Massari F; Tartari F; Cerqueti R; Lopez-Beltran A; Cheng L; Montironi R
Curr Drug Metab; 2019; 20(4):305-312. PubMed ID: 30799789
[TBL] [Abstract][Full Text] [Related]
6. Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment.
Gevaert T; Montironi R; Lopez-Beltran A; Van Leenders G; Allory Y; De Ridder D; Claessens F; Kockx M; Akand M; Joniau S; Netto G; Libbrecht L
Semin Cancer Biol; 2018 Oct; 52(Pt 2):216-227. PubMed ID: 29032188
[TBL] [Abstract][Full Text] [Related]
7. Toward personalized management in bladder cancer: the promise of novel molecular taxonomy.
Eich ML; Dyrskjøt L; Netto GJ
Virchows Arch; 2017 Aug; 471(2):271-280. PubMed ID: 28429075
[TBL] [Abstract][Full Text] [Related]
8. Inside the 2015 ASCO Genitourinary Cancers Symposium.
Santoni M; Massari F; Iacovelli R; Ciccarese C; Verri E; Burattini L; Montironi R; Nolè F; Tortora G; Cascinu S
Future Oncol; 2015; 11(13):1859-62. PubMed ID: 26161923
[TBL] [Abstract][Full Text] [Related]
9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
10. Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.
Paolillo C; Londin E; Fortina P
Scand J Clin Lab Invest Suppl; 2016; 245():S84-91. PubMed ID: 27542004
[TBL] [Abstract][Full Text] [Related]
11. An Overview of Emerging Immunotargets of Genitourinary Tumors.
Montironi R; Santoni M; Cheng L; Lopez-Beltran A; Massari F; Matrana MR; Moch H; Scarpelli M
Curr Drug Targets; 2016; 17(7):750-6. PubMed ID: 26648079
[TBL] [Abstract][Full Text] [Related]
12. Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review.
Syn NL; Yong WP; Goh BC; Lee SC
Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):911-22. PubMed ID: 27249175
[TBL] [Abstract][Full Text] [Related]
13. Immunotargeting and personalized therapies in genitourinary cancers.
Mazzucchelli R; Gasparrini S; Galosi AB; Massari F; Ciccarese C; Scarpelli M; Lopez-Beltran A; Cheng L; Montironi R
Future Oncol; 2016 Aug; 12(16):1853-6. PubMed ID: 27113700
[No Abstract] [Full Text] [Related]
14. Genomic Analysis of Childhood Brain Tumors: Methods for Genome-Wide Discovery and Precision Medicine Become Mainstream.
Mack SC; Northcott PA
J Clin Oncol; 2017 Jul; 35(21):2346-2354. PubMed ID: 28640705
[TBL] [Abstract][Full Text] [Related]
15. Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises.
Santoni M; Scarpelli M; Mazzucchelli R; Lopez-Beltran A; Cheng L; Cascinu S; Montironi R
J Biol Regul Homeost Agents; 2014; 28(4):555-63. PubMed ID: 25620167
[TBL] [Abstract][Full Text] [Related]
16. Using circulating cell-free DNA to monitor personalized cancer therapy.
Oellerich M; Schütz E; Beck J; Kanzow P; Plowman PN; Weiss GJ; Walson PD
Crit Rev Clin Lab Sci; 2017 May; 54(3):205-218. PubMed ID: 28393575
[TBL] [Abstract][Full Text] [Related]
17. Application of patient-derived liver cancer cells for phenotypic characterization and therapeutic target identification.
Castven D; Becker D; Czauderna C; Wilhelm D; Andersen JB; Strand S; Hartmann M; Heilmann-Heimbach S; Roth W; Hartmann N; Straub BK; Mahn FL; Franck S; Pereira S; Haupts A; Vogel A; Wörns MA; Weinmann A; Heinrich S; Lang H; Thorgeirsson SS; Galle PR; Marquardt JU
Int J Cancer; 2019 Jun; 144(11):2782-2794. PubMed ID: 30485423
[TBL] [Abstract][Full Text] [Related]
18. [Precision medicine: A major step forward in specific situations, a myth in refractory cancers?].
Albin N; Mc Leer A; Sakhri L
Bull Cancer; 2018 Apr; 105(4):375-396. PubMed ID: 29501208
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in genitourinary tumors: A review focused on biology and systemic treatment.
González Del Alba A; Arranz JÁ; Puente J; Méndez-Vidal MJ; Gallardo E; Grande E; Pérez-Valderrama B; González-Billalabeitia E; Lázaro-Quintela M; Pinto Á; Lainez N; Piulats JM; Esteban E; Maroto Rey JP; García JA; Suárez C
Crit Rev Oncol Hematol; 2017 May; 113():171-190. PubMed ID: 28427506
[TBL] [Abstract][Full Text] [Related]
20. The International Society of Urological Pathology Consultation on Molecular Pathology of Urogenital Cancer.
van der Kwast TH; Egevad L; Kristiansen G; Grignon DJ
Am J Surg Pathol; 2020 Jul; 44(7):859-861. PubMed ID: 32341239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
